663 results on '"Peipp, Matthias"'
Search Results
202. Preclinical activity of the JAK1/2 inhibitor ruxolitinib on malignant plasma cell growth and survival.
203. Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression
204. Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity
205. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
206. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
207. Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing
208. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
209. The Novel Bispecific Antibody [(CD20)2xCD16] Efficiently Triggers Lysis of Neoplastic B Cells
210. The Novel JAK2 Inhibitor NVP-BSK805 Has Cytotoxic Activity on Malignant Plasma Cells
211. Maturation of Monocyte-Derived Dendritic Cells Induced by Dual Targeting of Endocytosis Receptor and CD40
212. Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis
213. Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.
214. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) againstKRAS-mutated tumor cells
215. A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and FcαRI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells
216. Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
217. The Immunotoxin HM1.24-ETA′ Is a Potent Inducer of Apoptosis in Malignant Plasma Cells
218. An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
219. A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells
220. PotentIn vitroandIn vivoActivity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
221. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
222. Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
223. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility
224. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
225. Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations
226. Efficient Lysis of Myeloma Cells by CD16 Positive Effector Cells with Recombinant Single Chain Bispecific Antibodies Targeting HM1.24.
227. XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.
228. Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.
229. Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor
230. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
231. Monitoring circulating γδT cells in cancer patients to optimize γδT cell-based immunotherapy.
232. γδ T cell-mediated antibody-dependent cellular cytotoxicity with CD19 antibodies assessed by an impedance-based label-free real-time cytotoxicity assay.
233. Engineered Antibody Derivatives in Preclinical and Clinical Development.
234. Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.
235. Target Cell–Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7
236. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor
237. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell–depleted allografts
238. Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications
239. Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function.
240. Mouse Immune Libraries for the Generation of ScFv Fragments Directed Against Human Cell Surface Antigens.
241. Bispecific antibodies targeting cancer cells
242. An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells
243. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
244. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
245. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 min(1) antibody.
246. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.
247. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.
248. ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.
249. Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini- Antibodies Directed against the AML Stem Cell Antigen CD96.
250. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.